TY  - JOUR 
AU  - López-Jaime, F.-J.
AU  - Benítez, O.
AU  - Díaz Jordán, B.L.
AU  - Montaño, A.
AU  - Coll, J.
AU  - Quintana París, L.
AU  - Gomez Del Castillo Solano, Mª Del Carmen
PY  - 2023
SN  - 1607-8454
UR  - http://hdl.handle.net/20.500.11940/21473
AB  - INTRODUCTION: Prophylaxis with emicizumab, a bispecific monoclonal antibody that mimics FVIII function, has shown encouraging results in clinical trials in terms of efficacy and safety. However, current experience is limited, and many areas of concern...
LA  - eng
KW  - Humans
KW  - Infant, Newborn
KW  - Antibodies, Bispecific
KW  - Factor VIII
KW  - Hemophilia A
KW  - Hemorrhage
TI  - Expert opinion paper on the treatment of hemophilia a with emicizumab
DO  - 10.1080/16078454.2023.2166334
T2  - Hematology (Amsterdam, Netherlands)
M2  - 2166334
KW  - AS A Coruña
KW  - INIBIC
VL  - 28
ER  -